Monte Rosa Therapeutics stock fell 3.89 percent as analysts kept targets high

Published on 10/07/2026 at 03:41 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Monte Rosa Therapeutics stock traded at USD 9.87 on October 6, 2026, after Q2 revenue reached USD 8.97 million against USD 12.91 million consensus. Analysts set a USD 28.00 average target.

GLUE, US61225M1027, Illustration mit AI erstellt.

Monte Rosa Therapeutics stock (ISIN US61225M1027) closed at USD 9.87 on Nasdaq on October 6, 2026, down 3.89 percent from the previous session. The latest company update centers on MRT-8102, while second-quarter results and analyst estimates show the valuation debate facing the clinical-stage biotechnology company.

Q2 revenue missed consensus

Monte Rosa reported second-quarter 2026 revenue of USD 8.97 million and a diluted GAAP loss of USD 0.43 per share. According to MarketBeat on October 5, 2026, the quarter missed consensus of a USD 0.38 loss per share, while revenue consensus stood at USD 12.91 million.

The earnings gap matters because the company remains dependent on clinical progress rather than recurring product sales. Its Q2 net loss was USD 43.4 million, according to MarketBeat, making cash use and development milestones central to the stock story.

MRT-8102 advances into Phase 2

A Form 8-K dated October 1, 2026, said the GFORCE-1 Phase 1 study enrolled 108 participants. The filing from StockTitan reported median NEK7 degradation of 80 percent to 90 percent across the tested dose levels and an 85 percent median reduction in hsCRP.

The same filing described treatment-emergent adverse events in 33 percent of MRT-8102 participants versus 30 percent of placebo participants, with no serious adverse events reported. Monte Rosa plans Phase 2 development in coronary artery disease, gout and hidradenitis suppurativa, but those programs remain clinical-stage projects rather than approved products.

Analysts see a wide valuation gap

MarketBeat reported on October 5, 2026, that the consensus rating was Moderate Buy across 10 analysts, with an average price target of USD 28.00. That target lies 183.7 percent above the October 6 price of USD 9.87, a gap that reflects the market's high sensitivity to trial execution.

HC Wainwright maintained a Strong Buy view and forecast a Q3 2026 loss of USD 0.45 per share, according to MarketBeat on October 5, 2026. The bullish target case therefore depends on clinical milestones overcoming the companys current losses and revenue shortfall.

Stock closes near its yearly low

Monte Rosa Therapeutics stock closed at USD 9.87 on Nasdaq on October 6, 2026, with a session range of USD 9.78 to USD 10.38. The 52-week range was USD 7.24 to USD 25.77, while volume reached 1,049,014 shares.